Home
Events
Virtual Seminar "The changing landscape in the treatment of relapsed refractory DLBCL in 2026"
Virtual Seminar "The changing landscape in the treatment of relapsed refractory DLBCL in 2026"
Thanks to our main sponsor Roche and our sponsor Abbvie for helping make this seminar possible!
The Belgian Hematology Society is pleased to invite you to the Virtual Seminar "The changing landscape in the treatment of relapsed refractory DLBCL in 2026"on Wednesday, January 7, 2026, online.
Who can join? BHS members who are clinical Hematologists and hematologists in training.
What’s the aim? The BHS Lymphoma Committee organizes this webinar for Belgian hematologists, featuring Prof. Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York. The symposium will focus on the evolving treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Provisional Program
- 19:30-19:35 : Welcome - Dr Sylvia Snauwaert (AZ Sint.Jan Brugge)
- 19:35-20:05 : Prof. Gilles Salles’ Presentation on “The changing landscape in the treatment of relapsed refractory DLBCL in 2026” - Prof. Gilles Salles (Memorial Sloan Kettering Cancer Center, New York)
- 20:05 - 20:30 : Discussions and Q&A - Dr Sylvia Snauwaert (AZ Sint.Jan Brugge) & Prof. Gilles Salles (Memorial Sloan Kettering Cancer Center, New York)